Insurance Companies

The Evidence of Clinical Research and IORT

Faster procedures and proven reliability resulting in better outcomes not only provides some peace of mind for the patient and facility, but they remain imperative for the payer. And research proves that IORT with electrons better serves certain patients and benefits the business of healthcare.

But it’s not our word that tells the whole story. Rather the story of IORT and electrons is one based in solid, long-term clinical research in multiple indications of cancer. The most mature and robust evidence exists for breast cancer and all IORT boost studies indicate that IORT boost results in superior local control compared to conventional EBRT boost while retaining excellent cosmesis. Better local control means lower rates of recurrence and fewer salvage mastectomies.

Leading Institutions Agree

Mobetron and its electron-based IORT technology is currently employed by leading medical institutions such as Mayo Clinic, University of California San Francisco, Massachusetts General Hospital, Stanford University Medical Center, OHSU and dozens of other locations in the United States and worldwide.

FDA Classification

Mobetron is classified by the FDA as a medical charged particle accelerator and received approval in 1998. As of 2013, IORT has been approved and coded for Medicare reimbursement. Medicare uses the Medicare Physician Fee Schedule (MPFS) to reimburse for physician services. IORT has an established history of reimbursement by private health insurance payers.